Drug intelligence / Profile preview

cetirizine + paracetamol + phenylephrine

Development stage
Unknown
Lead developer
Boffin Biotech
Modality
Small Molecules
Administration
Oral
01

Overview

Cad Cold is an oral fixed-dose combination therapy developed by Boffin Biotech for the symptomatic relief of the common cold, influenza, and upper respiratory allergies. It is formulated as a tablet containing paracetamol (an analgesic and antipyretic), phenylephrine (a nasal decongestant), and cetirizine (a second-generation antihistamine). Paracetamol acts centrally to reduce fever and alleviate pain by inhibiting prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the nasal mucosa, thereby reducing nasal congestion and swelling. Cetirizine is a selective peripheral H1 histamine receptor antagonist that prevents allergic symptoms such as sneezing, runny nose, and watery eyes without causing significant sedation.

Brand names
Cad ColdKuffery ColdPetacold-C
Other names
cetirizine + paracetamol + phenylephrinecetirizine/paracetamol/phenylephrineparacetamol + phenylephrine + cetirizineparacetamol/phenylephrine/cetirizine
02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on cetirizine + paracetamol + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetirizine + paracetamol + phenylephrine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call